|
|
|
Volumn 5, Issue 12, 2004, Pages 1340-1347
|
|
MS-209 Schering
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
5 [3 (4 DIPHENYLACETYL 1 PIPERAZINYL) 2 HYDROXYPROPOXY]QUINOLINE;
ANTHRACYCLINE DERIVATIVE;
ANTINEOPLASTIC AGENT;
BIRICODAR;
CYCLOPHOSPHAMIDE;
CYCLOSPORIN;
DAUNORUBICIN;
DEXVERAPAMIL;
DOCETAXEL;
DOXORUBICIN;
ELACRIDAR;
ENZYME INHIBITOR;
ETOPOFOS;
ETOPOSIDE;
FLUOROURACIL;
GLYCOPROTEIN P INHIBITOR;
IMATINIB;
MULTIDRUG RESISTANCE PROTEIN 1;
PACLITAXEL;
QUININE;
QUINOLINE DERIVATIVE;
QUINOLONE DERIVATIVE;
SPHINGOMYELIN SYNTHETASE INHIBITOR;
TACROLIMUS;
TARIQUIDAR;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
VALSPODAR;
VERAPAMIL;
VINCRISTINE;
ZOSUQUIDAR;
AREA UNDER THE CURVE;
BREAST CANCER;
CLINICAL TRIAL;
DOSE RESPONSE;
DRUG BIOAVAILABILITY;
DRUG BLOOD LEVEL;
DRUG CONTRAINDICATION;
DRUG MECHANISM;
DRUG METABOLISM;
DRUG POTENTIATION;
DRUG STRUCTURE;
DRUG SYNTHESIS;
DYSPHAGIA;
FATIGUE;
HUMAN;
INFECTION;
LARYNX CANCER;
LUNG NON SMALL CELL CANCER;
MAXIMUM PERMISSIBLE DOSE;
MULTIDRUG RESISTANCE;
NEUTROPENIA;
NONHUMAN;
QUANTITATIVE STRUCTURE ACTIVITY RELATION;
REVIEW;
STOMATITIS;
ANIMALS;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS, PHASE II;
DRUGS, INVESTIGATIONAL;
HUMANS;
QUINOLINES;
|
|
EID: 11344290236
PISSN: 14724472
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (21)
|
|
References (0)
|
